ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Insulin-like factor 3, luteinizing hormone and testosterone in testicular cancer patients: effects of b-hCG and cancer treatment
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 133478" data-attributes="member: 13851"><p><strong>SUMMARY</strong></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Background:</span></strong> Primary hypogonadism (low testosterone and high luteinizing hormone, LH) is present in approximately 20% of testicular cancer (TC) survivors after orchidectomy with or without chemotherapy. </p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Objectives:</span></strong> We investigated insulin-like factor 3 (INSL3), a novel marker of Leydig cell function, in TC patients. Materials and Methods: We analyzed: (I) a cross-sectional cohort of TC patients after orchidectomy with or without chemotherapy (1988–1999) at long-term follow-up (median 36 and 35 years of age at follow-up, respectively) and healthy men of similar age; (II) a longitudinal cohort of chemotherapy-treated TC patients (2000–2008), analyzed before and 1 year after chemotherapy (median 29 years of age at chemotherapy). INSL3, testosterone, and LH were compared between groups and over time and related to pre-chemotherapy b-hCG levels. </p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Results:</span></strong> In the cross-sectional cohort, TC patients at median 7 years after orchidectomy and chemotherapy (n = 79) had higher LH (p < 0.001), lower testosterone (p = 0.001), but similar INSL3 as controls (n = 40). After orchidectomy only (n=25), higher LH (p = 0.02), but no differences in testosterone or INSL3 were observed compared to controls. In the longitudinal cohort, patients with normal pre-chemotherapy b-hCG (≤5 mU/L, n = 35) had increased LH 1 year after chemotherapy compared to pre-chemotherapy (p = 0.001), and no change in testosterone or INSL3. In contrast, patients with high b-hCG pre-chemotherapy (n = 42) had suppressed LH, markedly elevated testosterone, and low INSL3 at start of chemotherapy, with increased LH, decreased testosterone, and increased INSL3 1 year later (all p < 0.001). </p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Discussion: </span></strong>Changes in LH show that gonadal endocrine function is disturbed before chemotherapy, 1 year later, and at long-term follow-up in chemotherapy-treated TC patients.</p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Conclusion: </span></strong>Pre-chemotherapy, b-hCG-producing tumors affect the gonadal endocrine axis, demonstrated by increased testosterone and decreased LH. INSL3 did not uniformly follow the pattern of testosterone</p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p>In conclusion, changes in LH show that gonadal endocrine function is disturbed before chemotherapy, 1 year later and at long-term follow-up in chemotherapy-treated TC patients. Pre-chemotherapy, b-hCG-producing tumors affect the gonadal endocrine axis, demonstrated by increased testosterone and decreased LH. Remarkably, INSL3 as a marker of Leydig cell activity and differentiation is simultaneously suppressed. INSL3 does not seem to be a suitable marker to predict hypogonadism as a late effect of chemotherapy in TC patients. After longer follow-up, INSL3 levels are comparable to levels in healthy men, implicating potentially ongoing Leydig cell recovery more than 2 years after treatment.</p></blockquote><p></p>
[QUOTE="madman, post: 133478, member: 13851"] [B]SUMMARY[/B] [B][COLOR=rgb(184, 49, 47)]Background:[/COLOR][/B] Primary hypogonadism (low testosterone and high luteinizing hormone, LH) is present in approximately 20% of testicular cancer (TC) survivors after orchidectomy with or without chemotherapy. [B][COLOR=rgb(184, 49, 47)]Objectives:[/COLOR][/B] We investigated insulin-like factor 3 (INSL3), a novel marker of Leydig cell function, in TC patients. Materials and Methods: We analyzed: (I) a cross-sectional cohort of TC patients after orchidectomy with or without chemotherapy (1988–1999) at long-term follow-up (median 36 and 35 years of age at follow-up, respectively) and healthy men of similar age; (II) a longitudinal cohort of chemotherapy-treated TC patients (2000–2008), analyzed before and 1 year after chemotherapy (median 29 years of age at chemotherapy). INSL3, testosterone, and LH were compared between groups and over time and related to pre-chemotherapy b-hCG levels. [B][COLOR=rgb(184, 49, 47)]Results:[/COLOR][/B] In the cross-sectional cohort, TC patients at median 7 years after orchidectomy and chemotherapy (n = 79) had higher LH (p < 0.001), lower testosterone (p = 0.001), but similar INSL3 as controls (n = 40). After orchidectomy only (n=25), higher LH (p = 0.02), but no differences in testosterone or INSL3 were observed compared to controls. In the longitudinal cohort, patients with normal pre-chemotherapy b-hCG (≤5 mU/L, n = 35) had increased LH 1 year after chemotherapy compared to pre-chemotherapy (p = 0.001), and no change in testosterone or INSL3. In contrast, patients with high b-hCG pre-chemotherapy (n = 42) had suppressed LH, markedly elevated testosterone, and low INSL3 at start of chemotherapy, with increased LH, decreased testosterone, and increased INSL3 1 year later (all p < 0.001). [B][COLOR=rgb(184, 49, 47)]Discussion: [/COLOR][/B]Changes in LH show that gonadal endocrine function is disturbed before chemotherapy, 1 year later, and at long-term follow-up in chemotherapy-treated TC patients. [B][COLOR=rgb(184, 49, 47)]Conclusion: [/COLOR][/B]Pre-chemotherapy, b-hCG-producing tumors affect the gonadal endocrine axis, demonstrated by increased testosterone and decreased LH. INSL3 did not uniformly follow the pattern of testosterone In conclusion, changes in LH show that gonadal endocrine function is disturbed before chemotherapy, 1 year later and at long-term follow-up in chemotherapy-treated TC patients. Pre-chemotherapy, b-hCG-producing tumors affect the gonadal endocrine axis, demonstrated by increased testosterone and decreased LH. Remarkably, INSL3 as a marker of Leydig cell activity and differentiation is simultaneously suppressed. INSL3 does not seem to be a suitable marker to predict hypogonadism as a late effect of chemotherapy in TC patients. After longer follow-up, INSL3 levels are comparable to levels in healthy men, implicating potentially ongoing Leydig cell recovery more than 2 years after treatment. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Insulin-like factor 3, luteinizing hormone and testosterone in testicular cancer patients: effects of b-hCG and cancer treatment
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top